DSigDB Home
Search Gene
Collections
Browse Gene Sets
Download
Help

Gene Set: D4 : CTD - fluvastatin


Collection D4 : CTD
Chemical Name fluvastatin ( From PubChem : AC1L1FUW )
FDA NPC WHO Indian Australia China Traditional
Herbal
Clinical
Trail
NotNotNotNotNotNotNotNot
Molecular
Weight
Hydrogen Bond
Donor Count
Hydrogen Bond
Acceptor Count
cLogP Lipinski Rule
411.466 g/mol 3 5 4.6281 True
Structure
InChI InChI=1S/C24H26FNO4/c1-15(2)26-21-6-4-3-5-20(21)24(16-7-9-17(25)10-8-16)22(26)12-11-18(27)13-19(28)14-23(29)30/h3-12,15,18-19,27-28H,13-14H2,1-2H3,(H,29,30)/b12-11+/t18-,19+/m1/s1
InChIKey FJLGEFLZQAZZCD-VVZAMHAXSA-N
Links

Gene (76 / 151)


⊖ Less

Source Type Unit Value Gene PMID Assay Other
CTDaffects(cotreatment)ABCA1
C065180
CTDaffects(response to substance)ABCA1
C065180
CTDaffects(import)ABCB11
C065180
CTDdecreases(reaction)ABCB11
C065180
CTDdecreases(activity)ABCB11
C065180
CTDaffects(binding)ABCC2
C065180
CTDincreases(uptake)ABCC2
C065180
CTDdecreases(reaction)ABCC2
C065180
CTDaffects(cotreatment)APOB
C065180
CTDaffects(response to substance)APOB
C065180
CTDaffects(cotreatment)APOB
C065180
CTDdecreases(expression)APOB
C065180
CTDincreases(reaction)APOB
C065180
CTDaffects(cotreatment)APOE
C065180
CTDaffects(response to substance)APOE
C065180
CTDincreases(expression)APOE
C065180
CTDaffects(cotreatment)ARHGAP29
C065180
CTDincreases(expression)ARHGAP29
C065180
CTDaffects(cotreatment)ARHGEF12
C065180
CTDincreases(expression)ARHGEF12
C065180
CTDaffects(cotreatment)ARHGEF3
C065180
CTDincreases(expression)ARHGEF3
C065180
CTDaffects(cotreatment)BCAP29
C065180
CTDincreases(expression)BCAP29
C065180
CTDaffects(cotreatment)BCL2L11
C065180
CTDincreases(expression)BCL2L11
C065180
CTDaffects(cotreatment)BHLHE40
C065180
CTDincreases(expression)BHLHE40
C065180
CTDaffects(cotreatment)BUB1
C065180
CTDincreases(expression)BUB1
C065180
CTDaffects(cotreatment)CASP1
C065180
CTDincreases(expression)CASP1
C065180
CTDaffects(cotreatment)CDK2AP2
C065180
CTDincreases(expression)CDK2AP2
C065180
CTDaffects(cotreatment)CETP
C065180
CTDaffects(response to substance)CETP
C065180
CTDaffects(cotreatment)CKS2
C065180
CTDincreases(expression)CKS2
C065180
CTDincreases(expression)CYP2B6
C065180
CTDaffects(metabolic processing)CYP2C9
C065180
CTDdecreases(reaction)CYP2C9
C065180
CTDaffects(metabolic processing)CYP3A4
C065180
CTDdecreases(reaction)CYP3A4
C065180
CTDdecreases(activity)CYP3A4
C065180
CTDaffects(cotreatment)EMP3
C065180
CTDincreases(expression)EMP3
C065180
CTDaffects(cotreatment)ERCC5
C065180
CTDincreases(expression)ERCC5
C065180
CTDaffects(cotreatment)ERG
C065180
CTDincreases(expression)ERG
C065180
CTDaffects(cotreatment)FDFT1
C065180
CTDincreases(expression)FDFT1
C065180
CTDaffects(cotreatment)FNTA
C065180
CTDincreases(expression)FNTA
C065180
CTDaffects(cotreatment)GADD45B
C065180
CTDincreases(expression)GADD45B
C065180
CTDaffects(cotreatment)HMGCR
C065180
CTDaffects(response to substance)HMGCR
C065180
CTDdecreases(activity)HMGCR
C065180
CTDaffects(cotreatment)IGF1
C065180
CTDincreases(expression)IGF1
C065180
CTDaffects(cotreatment)IGFBP5
C065180
CTDincreases(expression)IGFBP5
C065180
CTDaffects(cotreatment)IL10RA
C065180
CTDincreases(expression)IL10RA
C065180
CTDaffects(cotreatment)IL2RG
C065180
CTDincreases(expression)IL2RG
C065180
CTDaffects(cotreatment)KAT2B
C065180
CTDincreases(expression)KAT2B
C065180
CTDaffects(cotreatment)LDLR
C065180
CTDaffects(response to substance)LDLR
C065180
CTDaffects(binding)LDLR
C065180
CTDincreases(reaction)LDLR
C065180
CTDincreases(activity)LDLR
C065180
CTDaffects(cotreatment)LIPC
C065180
CTDaffects(response to substance)LIPC
C065180
CTDdecreases(farnesylation)LMNA
C065180
CTDaffects(cotreatment)LPL
C065180
CTDaffects(response to substance)LPL
C065180
CTDaffects(cotreatment)LZTS1
C065180
CTDincreases(expression)LZTS1
C065180
CTDdecreases(expression)MCL1
C065180
CTDaffects(cotreatment)MED23
C065180
CTDincreases(expression)MED23
C065180
CTDaffects(cotreatment)MPHOSPH8
C065180
CTDincreases(expression)MPHOSPH8
C065180
CTDaffects(cotreatment)MPP5
C065180
CTDincreases(expression)MPP5
C065180
CTDaffects(cotreatment)NDC80
C065180
CTDincreases(expression)NDC80
C065180
CTDincreases(activity)NR1I2
C065180
CTDincreases(activity)NR1I3
C065180
CTDaffects(cotreatment)OPTN
C065180
CTDincreases(expression)OPTN
C065180
CTDaffects(cotreatment)PAPPA2
C065180
CTDincreases(expression)PAPPA2
C065180
CTDaffects(cotreatment)PCSK9
C065180
CTDaffects(response to substance)PCSK9
C065180
CTDaffects(binding)PPARA
C065180
CTDincreases(activity)PPARA
C065180
CTDincreases(reaction)PPARA
C065180
CTDaffects(cotreatment)PPP1R15A
C065180
CTDincreases(expression)PPP1R15A
C065180
CTDaffects(cotreatment)PRDX3
C065180
CTDincreases(expression)PRDX3
C065180
CTDincreases(expression)PROCR
C065180
CTDaffects(cotreatment)RAB27B
C065180
CTDincreases(expression)RAB27B
C065180
CTDaffects(cotreatment)RAB32
C065180
CTDincreases(expression)RAB32
C065180
CTDaffects(cotreatment)RAB5B
C065180
CTDincreases(expression)RAB5B
C065180
CTDaffects(cotreatment)RABGAP1L
C065180
CTDincreases(expression)RABGAP1L
C065180
CTDdecreases(prenylation)RAP1A
C065180
CTDdecreases(phosphorylation)RB1
C065180
CTDaffects(cotreatment)RGS11
C065180
CTDincreases(expression)RGS11
C065180
CTDaffects(cotreatment)RHOB
C065180
CTDincreases(expression)RHOB
C065180
CTDaffects(cotreatment)RIMS2
C065180
CTDincreases(expression)RIMS2
C065180
CTDaffects(cotreatment)RIN2
C065180
CTDincreases(expression)RIN2
C065180
CTDaffects(binding)RXRA
C065180
CTDincreases(activity)RXRA
C065180
CTDincreases(reaction)RXRA
C065180
CTDdecreases(activity)SLC15A1
C065180
CTDdecreases(reaction)SLCO1B1
C065180
CTDincreases(response to substance)SLCO1B1
C065180
CTDincreases(uptake)SLCO1B1
C065180
CTDaffects(import)SLCO1B1
C065180
CTDaffects(import)SLCO1B3
C065180
CTDaffects(import)SLCO2B1
C065180
CTDaffects(cotreatment)SOS2
C065180
CTDincreases(expression)SOS2
C065180
CTDaffects(cotreatment)SPIN2A
C065180
CTDincreases(expression)SPIN2A
C065180
CTDaffects(cotreatment)STK17A
C065180
CTDincreases(expression)STK17A
C065180
CTDincreases(expression)TFPI
C065180
CTDaffects(cotreatment)TNFRSF10A
C065180
CTDincreases(expression)TNFRSF10A
C065180
CTDaffects(cotreatment)TP53INP1
C065180
CTDincreases(expression)TP53INP1
C065180
CTDaffects(cotreatment)WNT11
C065180
CTDincreases(expression)WNT11
C065180
PubChem AhR Potency (uM)uM40.856AHR-GI(Protien) :
PubChem NoneuMCYP19A1-GI(Protien) :
PubChem NoneuMNR3C1-GI(Protien) :
PubChem NoneuMPPARG-GI(Protien) :
Download gene sets gmt, text, Detailed text
Contact us
Tan Lab , Mail Stop 8117
12801 East 17th Avenue
Division of Medical Oncology , Department of Medicine
University of Colorado School of Medicine
Aurora, CO 80045, USA

* Best viewed in the latest version of Chrome (42+), Safari (8+), IE (11+) or Firefox (35+).